Former American hedge fund manager Martin Shkreli bought the rights for Daraprim and raised its price by 5000% over a month. The drug is used by people who have weakened immune systems— most notably AIDS. It was initially developed by GlaxoSmithKline for $1, after which it traded hands twice, before Turing Pharmaceuticals increased its price from $13.5 to $750.